Lercanidipine Orion

Lercanidipine, the active ingredient in Lercanidipine Orion, is a calcium channel blocker presented as an oral tablet for oral use. It is indicated for the management of hypertension in adult patients, helping to lower elevated blood pressure by relaxing vascular smooth muscle.

GNH USA supplies Lercanidipine Orion as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent quality and regulatory compliance.

Lercanidipine acts on the cardiovascular system to lower blood pressure in hypertensive patients.

Essential hypertension: reduces both systolic and diastolic blood pressure. Isolated systolic hypertension: helps achieve target systolic levels. Secondary hypertension (e.g., renal): contributes to blood pressure control as part of combination therapy.

Adverse reactions reported with Lercanidipine Orion vary in frequency and severity.

Common Side Effects: - Headache: mild to moderate headache may occur. - Flushing: transient warmth and reddening of the skin. - Peripheral edema: swelling of the ankles or feet. - Dizziness: sensation of light‑headedness, especially after standing.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure requiring medical attention. - Angioedema: swelling of the face, lips, tongue or throat. - Myocardial infarction: rare occurrence of heart attack symptoms.

When prescribing Lercanidipine Orion, clinicians should consider several precautionary measures. - Monitor blood pressure: adjust therapy based on regular measurements. - Avoid abrupt discontinuation: sudden stop may cause rebound hypertension. - Caution in hepatic impairment: reduced metabolism may increase exposure. - Use with caution in elderly patients: increased sensitivity to hypotensive effects. - Pregnancy and lactation: safety not established; avoid unless benefits outweigh risks. - Store at ambient temperature: keep in original packaging, protect from moisture and light.

Lercanidipine Orion may interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise plasma concentrations. - Co‑administration with other antihypertensives that cause additive hypotension. - Grapefruit juice: can increase drug exposure and risk of adverse effects.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce therapeutic effect. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may blunt antihypertensive response. - Diuretics: may enhance risk of electrolyte disturbances when combined.